253 related articles for article (PubMed ID: 29330785)
21. Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites.
Pappalardi MB; McNulty DE; Martin JD; Fisher KE; Jiang Y; Burns MC; Zhao H; Ho T; Sweitzer S; Schwartz B; Annan RS; Copeland RA; Tummino PJ; Luo L
Biochem J; 2011 Jun; 436(2):363-9. PubMed ID: 21410436
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of hypoxia-inducible factor-prolyl hydroxylation protects from cyclophosphamide-induced bladder injury and urinary dysfunction.
Clayton DB; Tong CMC; Li B; Taylor AS; De S; Mason MD; Dudley AG; Davidoff O; Kobayashi H; Haase VH
Am J Physiol Renal Physiol; 2022 Jul; 323(1):F81-F91. PubMed ID: 35499237
[TBL] [Abstract][Full Text] [Related]
23. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.
Haase VH
Exp Cell Res; 2017 Jul; 356(2):160-165. PubMed ID: 28483447
[TBL] [Abstract][Full Text] [Related]
25. Oxygen-sensitive reset of hypoxia-inducible factor transactivation response: prolyl hydroxylases tune the biological normoxic set point.
Khanna S; Roy S; Maurer M; Ratan RR; Sen CK
Free Radic Biol Med; 2006 Jun; 40(12):2147-54. PubMed ID: 16785028
[TBL] [Abstract][Full Text] [Related]
26. HIF-prolyl hydroxylases and cardiovascular diseases.
Sen Banerjee S; Thirunavukkarasu M; Tipu Rishi M; Sanchez JA; Maulik N; Maulik G
Toxicol Mech Methods; 2012 Jun; 22(5):347-58. PubMed ID: 22424133
[TBL] [Abstract][Full Text] [Related]
27. β-N-oxalyl-L-α, β- diaminopropionic acid induces HRE expression by inhibiting HIF-prolyl hydroxylase-2 in normoxic conditions.
Eslavath RK; Sharma D; Bin Omar NAM; Chikati R; Teli MK; Rajanikant GK; Singh SS
Eur J Pharmacol; 2016 Nov; 791():405-411. PubMed ID: 27393459
[TBL] [Abstract][Full Text] [Related]
28. The stabilization of hypoxia inducible factor modulates differentiation status and inhibits the proliferation of mouse embryonic stem cells.
Binó L; Kučera J; Štefková K; Švihálková Šindlerová L; Lánová M; Kudová J; Kubala L; Pacherník J
Chem Biol Interact; 2016 Jan; 244():204-14. PubMed ID: 26723917
[TBL] [Abstract][Full Text] [Related]
29. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
Aprelikova O; Chandramouli GV; Wood M; Vasselli JR; Riss J; Maranchie JK; Linehan WM; Barrett JC
J Cell Biochem; 2004 Jun; 92(3):491-501. PubMed ID: 15156561
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
Rabinowitz MH
J Med Chem; 2013 Dec; 56(23):9369-402. PubMed ID: 23977883
[TBL] [Abstract][Full Text] [Related]
31. Prolyl-hydroxylase PHD3 interacts with pyruvate dehydrogenase (PDH)-E1β and regulates the cellular PDH activity.
Kikuchi D; Minamishima YA; Nakayama K
Biochem Biophys Res Commun; 2014 Aug; 451(2):288-94. PubMed ID: 25088999
[TBL] [Abstract][Full Text] [Related]
32. Differential in vitro and cellular effects of iron chelators for hypoxia inducible factor hydroxylases.
Cho EA; Song HK; Lee SH; Chung BH; Lim HM; Lee MK
J Cell Biochem; 2013 Apr; 114(4):864-73. PubMed ID: 23097160
[TBL] [Abstract][Full Text] [Related]
33. HIF hydroxylation and cellular oxygen sensing.
Metzen E; Ratcliffe PJ
Biol Chem; 2004; 385(3-4):223-30. PubMed ID: 15134335
[TBL] [Abstract][Full Text] [Related]
34. Oxygen sensors as therapeutic targets in kidney disease.
Haase VH
Nephrol Ther; 2017 Apr; 13 Suppl 1():S29-S34. PubMed ID: 28577740
[TBL] [Abstract][Full Text] [Related]
35. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
36. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2.
Hou P; Kuo CY; Cheng CT; Liou JP; Ann DK; Chen Q
PLoS One; 2014; 9(11):e113865. PubMed ID: 25420025
[TBL] [Abstract][Full Text] [Related]
37. Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis.
Muz B; Larsen H; Madden L; Kiriakidis S; Paleolog EM
Arthritis Rheum; 2012 Sep; 64(9):2856-67. PubMed ID: 22488178
[TBL] [Abstract][Full Text] [Related]
38. Changes in Hypoxia-Inducible Factor-1 (HIF-1) and Regulatory Prolyl Hydroxylase (PHD) Enzymes Following Hypoxic-Ischemic Injury in the Neonatal Rat.
Chu HX; Jones NM
Neurochem Res; 2016 Mar; 41(3):515-22. PubMed ID: 26108712
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival.
Andersen S; Donnem T; Stenvold H; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
PLoS One; 2011; 6(8):e23847. PubMed ID: 21887331
[TBL] [Abstract][Full Text] [Related]
40. Novel Dioxygenases, HIF-α Specific Prolyl-hydroxylase and Asparanginyl-hydroxylase: O
Park H
Toxicol Res; 2008 Jun; 24(2):101-107. PubMed ID: 32038783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
